Metabolic bone disease (MBD) in the newborn predominantly affects preterm neonates, although there are a few reports of babies with congenital rickets after maternal vitamin D deficiency. Features of MBD in preterm neonates include radiological abnormalities such as fractures, rickets, and osteoporosis; biochemical features such as raised blood alkaline phosphatase activity or hypophosphataemia; skeletal deformity such as rib cage softening and altered head shape; and diminished linear growth velocity.
MBD can arise from insufficient dietary minerals (calcium and or phosphorus), too little collagen, or abnormal collagen.
MBD mainly arises from dietary mineral deficiency in the newborn, although copper deficiency, as a result of abnormal collagen metabolism, has also been implicated. It is difficult to differentiate these two processes, because they often occur in the same patient.
The pathology of MBD in preterm neonates shows generalised skeletal mineralisation, a reduction in the amount of osseous tissue (osteoporosis), and a disordered metaphyseal cartilage plate similar to that seen in classic rickets. I Nutritional aetiology of MBD in preterm neonates MINERAL 
DEFICIENCY
In 1980 Steichen, Gratton, and Tsang directly examined the effect of dietary mineral enhancement on bone mineralisation.2 Having contrasted the exponential requirement for calcium in utero (between 3-25 and 3-9 mmmol/kg/day) with the usual estimated postnatal dietary calcium retentions (between 1 6 and 2-5 mmol/kg/day), they supplemented formula milk with calcium (41.5 mmol/l) and phosphorus (20 mmol/l) and were able to show, using photon absorptiometry, peripheral skeletal bone mineral accretion equivalent to that in utero.2 Without dietary mineral enhancement, bone mineral accretion is negligible.3 In effect Steichen et al were mimicking the increase in total body calcium content from 5 g at 26 weeks of gestation, to 30 g at full term. The results of this small study have not been replicated by others, possibly because the control group had a lower bone mineral content before supplementation was started.
Using formal balance studies, other groups showed rates of calcium and phosphorus retention equivalent to those seen in utero, with milk contents of calcium (31 to 37-5 mmol/l) and phosphorus (21 to 27 mmoIl).45 These studies were the basis for the concentrations of calcium and phosphorus found in current preterm cow's milk formulas used in the United States. Levels in European formulas tend to be somewhat lower.
The hypothesis that the dietary mineral deficit relative to the in utero experience is responsible for MBD and bone mineral deficiency is based on calcium requirements. Calcium deficiency is very rare and has been described only after the accidental omission of calcium from parenteral nutrition solutions.6 Phosphorus deficiency has a more direct association with overt MBD and this is felt to be because phosphorus and calcium are taken up differentially by the skeleton and other tissues. Ninety eight per cent of body calcium is located in bone mineral compared with 85% of phosphorus; the other 15% resides in other tissues. Consequently, at very low mineral intakes, phosphorus deficiency arises first, as the lean tissues take priority, leaving little for the skeleton.
Phosphorus deficiency is seen in preterm neonates who are fed unfortified human milk,7 and during parenteral nutrition,8 when phosphorus intake may be as low as 0 5 mmol/kg/day, compared with the in utero requirement of 2-1 to 2-6 mmol/kg/day. Features Despite the original report,2 it has not been convincingly shown that in utero rates of bone mineral accretion can be achieved with such formulas. Although theoretically sound, such an approach is probably unnecessary given the rapid catchup in bone mineralisation, fall in alkaline phosphatase activity, and improved phosphorus concentration which occur after 40 weeks of conception and through early infancy. [23] [24] [25] [26] The catchup in bone mineralisation has been expressed in terms of forearm bone mineral content (BMC mg/cm) and in terms of whole body BMC.27 Sparse data on lumbar spinal bone mineral density (BMD mg/cm) also suggest rapid catchup to values in infants born at full term.28 Whether full catchup in BMD occurs in most infants remains to be established.
Pohlandt29 and Hillman et al30 have sug-
gested that in utero mineral accretion can only be achieved by using individually monitored supplementation with calcium and phosphorus, because of the natural interindividual variation in the processes of mineral absorption. Neonates who received doses adequate enough to permit simultaneous excretion of calcium (> 1 2 mmol/l) and phosphorus (>0 4 mmo/l) in more than half of urine specimens, achieved such levels of mineral accretion.29 Given the complicated nature of this approach and without good evidence of long term benefits, it does not seem suited to routine clinical practice. Additionally, balance studies are only snapshots of net mineral absorption, with little information about day to day variability in mineral absorption in neonates.
In summary, modest mineral augmentation prevents overt MBD. Given the rapid catchup in bone mineralisation which occurs in the first year, and given that its effectiveness has not been conclusively shown, attempting to match in utero bone mineral accretion may not be necessary. Enhanced calcium and phosphorus content of parenteral nutrition solutions reduces the risk and severity of MBD. Standard solutions contain up to 1 mmol/kg/day of both calcium and phosphorus. Enhancement to 1-9 mmol/kg/day calcium and 2-4 mmol/kg/day of phosphorus is associated with a reduction in the incidence of hypophosphataemia, fewer x-ray abnormalities, and improved bone mineralisation. 34 35 It has been calculated that to match in utero retention, 3 mmol/kg/day of calcium and 2-8 mmol/kg/day of phosphorus are required.36
This molar ratio, slightly in excess of 1, is generally considered to allow the best retention of calcium and phosphorus. The aim of treatment should be to keep the blood phosphorus concentration above 1 2 mmol/l.
To enhance parenteral nutrition solutions requires careful discussion with the pharmacy department as the solubility of calcium and phosphorus depends on other components within the solutions, the order in which they are combined, and the ambient temperature.
One way around this problem is to use organic phosphorus salts which do not precipitate with calcium, which are stable in solution37 and achieve equivalent retentions to standard salts in similar doses.38 Results of studies are awaited and must include assessment of urinary calcium excretion and the incidence of nephrocalcinosis. Hypercalcuria and nephrocalcinosis are associated with the use of parenteral nutrition in ill preterm neonates, and increased parenteral administration of calcium and phosphorus may increase the risk of these problems.
Vitamin Two studies have been conducted of breast feeding continued after discharge in preterm neonates, who had all been fed human milk with fortifier in the neonatal nursery. Both showed evidence of impaired mineralisation relative to formula fed infants. Blood phosphorus concentration was lower and serum alkaline phosphatase activity was higher throughout the first year of life.40 41 This, despite the ameliorating effect of a more varied diet with weaning.
Forearm bone mineral content was also lower at 1 year of age in human milk fed than in formula fed infants.4' The deficit in bone mineral content is fully established by 25 weeks of age, after which it remains relatively unchanged. This suggests that a relatively brief period of dietary mineral supplementation after discharge will prevent it. Calcium and phosphorus supplementation for breast fed infants during this period reduced hypophosphataemia from about 50% to 10%, and may be a useful Because the production of hydroxyapatite (bone mineral) produces metabolic acid and because preterm neonates are frequently acidotic, metabolic acidosis can be ameliorated by using phosphorus compounds which contain the smallest molar ratio of hydrogen ion.
